Density of dendritic cells around basal cell carcinomas is related to tumor size, anatomical site and stromal characteristics, and might be responsible for the response to topical therapy

International Journal of Dermatology

Volumn 47, Issue 12, 2008, Pages 1240-1244

  Rybka, Maria O ^a   Cintra, Maria L ^a   de Souza, Elemir M ^a   Metze, Konradin ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CELL DENSITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; FACE TUMOR; FEMALE; GENETIC STABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MYOFIBROBLAST; PATHOLOGICAL ANATOMY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CELL COUNT; FACIAL NEOPLASMS; FEMALE; HUMANS; LANGERHANS CELLS; MALE; MIDDLE AGED; SKIN NEOPLASMS;

EID: 57049119735     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03808.x     Document Type: Article

References (30)

1. Kaur P, Mulvaney M, Andrew CJ. Basal cell carcinoma progression correlates with host immune response and stromal alterations: A histologic analysis. Am J Dermatpathol 2006; 28: 293-307.
2. Metze K, Bedin V, Adam RL, et al. Parameters derived from the fast Fourier transform are predictive for the recurrence of basal cell carcinoma. Cell Oncol 2005; 27: 137.
3. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006; 45: 489-498.
4. Uhoda I, Quatresooz P, Pierard-Franchimont C, et al. Nudging epidermal field cancerogenesis by imiquimod. Dematology 2003; 206: 357-360.
5. Bukhardt Perez MP, Ruiz-Villaverde R, Naranjo Diaz MJ, et al. Basal cell carcinoma: Treatment with imiquimod. Int J Dermatol 2007; 46: 539-542.
6. Quatresooz P, Piérard GE. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol 2004; 28(s1): 27-29.
7. Vidal D, Matýas-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004; 29: 518-525.
8. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. J Am Acad Dermatol 1990; 23: 1118-1126.
9. Vassallo J, Pinto GA, Alvarenga M, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morph 2004; 12: 177-182.
10. Herreros FOC, Cintra ML, Adam RL, et al. Remodeling of the human dermis after application of salicylate Silanol. Arch Dermatol Res 2007; 299: 41-45.
11. Gil J, Barba J. Priciples of stereology. Computerized applications to anatomic pathology. In: Marchevsky AM, Bartels PH, eds. Image Analysis. A Primer for Pathologists. New York: Raven Press, 1994: 79-124.
12. Ackerman AB, Reddy VB, Soyer HP. Trichoblastic carcinoma. In: Ackerman AB, Reddy VB, Soyer HP, eds. Neoplasms with Follicular Differentiation. New York: Ardor Scribendi, 2001: 625-1005.
13. Oliveira GB, Pereira FG, Metze K, et al. Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. Cytometry 2001; 46: 329-335.
14. Lorand-Metze I, Metze K. AgNOR clusters as a parameter of cell kinetics in chronic lymphocytic leukaemia. J Clin Pathol Clin Mol Pathol 1996; 49: M357-M360.
15. Metze K, Lorand-Metze I. Age related decrease of AgNOR activity in acute and chronic lymphocytic leukaemias. J Clin Pathol Mol Pathol 1999; 52: 52.
16. De Rosa G, Barra E, Guarino M, et al. Fibronectin, laminin, type IV collagen distribution, and myofibroblastic stromal reaction in aggressive and nonaggressive basal cell carcinoma. Am J Dermatopathol 1994; 16: 258-267.
17. Metze K, Bedin V, Adam RL, et al. "Recurrent"basal cell carcinomas may represent new primary neoplasias: Differences between aggressive and non-aggressive histologic subtypes. J Plast Reconstr Aesthet Surg 2007; 60: 451-453.
18. Lorand-Metze I, Pinheiro MP, Ribeiro E, et al. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004; 28: 587-594.
19. Metze K, Lobo AM, Lorand-Metze I. Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia. Int J Cancer 2000; 89: 440-443.
20. Adam RL, Silva RC, Pereira FG, et al. The fractal dimension of nuclear chromatin as a prognostic factor in acute precursor B lymphoblastic leukemia. Cell Oncol 2006; 28: 55-59.
21. Metze K, Chiari AC, Andrade FL, et al. Changes in AgNOR configurations during the evolution and treatment of chronic lymphocytic leukemia. Hematol Cell Ther 1999; 41: 205-210.
22. Lorand-Metze I, Meira DG, Lima CS, et al. The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia. Haematologica 1999; 84: 564-565.
23. Vidal D, Matías-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: Outcome at 5-year follow-up. Arch Dermatol 2007; 143: 266-268.
24. Shumack S, Gebauer K, Quirk C, et al. 5% Imiquimod cream for the treatment of large superficial basal cell carcinoma. Arch Dermatol 2004; 140: 1286-1287.
25. Eigentler K, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57: 616-621.
26. Matsue H, Takashima A. Apoptosis in dendritic cell biology. J Dermatol Sci 1999; 20: 159-171.
27. Hermanns-Le T, Uhoda I, Pierard-Franchimont C, et al. Factor XIII a-positive dermal dendrocytes and shear wave propagation in human skin. Eur J Clin Invest 2002; 32: 847-851.
28. Weber A, Maurer M. Skin site mast cell numbers correlate with rates of nodular growth, but not incidence, of basal cell carcinoma. Dermatology 2005; 211: 298-299.
29. Silverman JS, Glusac EJ. Epithelioid cell histiocytoma - histogenetic and kinetics analysis of dermal microvascular unit dendritic cell subpopulations. J Cutan Pathol 2003; 30: 415-422.
30. Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: A 3-year retrospective follow-up study. Australas J Dermatol 2006; 47: 169-171.